Abstract
With the alarming resistance to currently used antibiotics, there is a serious worldwide threat to public health. Therefore, there is an urgent need to search for new antibiotics or new cellular targets which are essential for survival of the pathogens. However, during the past 50 years, only two new classes of antibiotics (oxazolidinone and lipopeptides) have reached the clinic. This suggests that the success rate in discovering new/novel antibiotics using conventional approaches is limited and that we must reconsider our antibiotic discovery approaches. While many new strategies are being pursued lately, this review primarily focuses only on a few of these novel/new approaches for antibiotic discovery. These include structure-based drug design (SBDD), the genomic approach, anti-virulence strategy, targeting nonmultiplying bacteria and the use of bacteriophages. In general, recent advancements in nuclear magnetic resonance, Xcrystallography, and genomic evolution have significant impact on antibacterial drug research. This review therefore aims to discuss recent strategies in searching new antibacterial agents making use of these technical novelties, their advantages, disadvantages and limitations.
Keywords: Acylated homoserine lactone, antibiotics, antibiotic discovery, antivirulence strategy, autoinducers, bacteriophages, genomic approach, non-multiplying bacteria, phage therapy, quorum sensing, resistance, screening strategies, structure-based drug design.
Current Medicinal Chemistry
Title:Renaissance in Antibiotic Discovery: Some Novel Approaches for Finding Drugs to Treat Bad Bugs
Volume: 22 Issue: 18
Author(s): Bharat Gadakh and Arthur Van Aerschot
Affiliation:
Keywords: Acylated homoserine lactone, antibiotics, antibiotic discovery, antivirulence strategy, autoinducers, bacteriophages, genomic approach, non-multiplying bacteria, phage therapy, quorum sensing, resistance, screening strategies, structure-based drug design.
Abstract: With the alarming resistance to currently used antibiotics, there is a serious worldwide threat to public health. Therefore, there is an urgent need to search for new antibiotics or new cellular targets which are essential for survival of the pathogens. However, during the past 50 years, only two new classes of antibiotics (oxazolidinone and lipopeptides) have reached the clinic. This suggests that the success rate in discovering new/novel antibiotics using conventional approaches is limited and that we must reconsider our antibiotic discovery approaches. While many new strategies are being pursued lately, this review primarily focuses only on a few of these novel/new approaches for antibiotic discovery. These include structure-based drug design (SBDD), the genomic approach, anti-virulence strategy, targeting nonmultiplying bacteria and the use of bacteriophages. In general, recent advancements in nuclear magnetic resonance, Xcrystallography, and genomic evolution have significant impact on antibacterial drug research. This review therefore aims to discuss recent strategies in searching new antibacterial agents making use of these technical novelties, their advantages, disadvantages and limitations.
Export Options
About this article
Cite this article as:
Gadakh Bharat and Aerschot Van Arthur, Renaissance in Antibiotic Discovery: Some Novel Approaches for Finding Drugs to Treat Bad Bugs, Current Medicinal Chemistry 2015; 22 (18) . https://dx.doi.org/10.2174/0929867322666150319115828
DOI https://dx.doi.org/10.2174/0929867322666150319115828 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Food Bioactives versus Drugs – Introduction
Current Pediatric Reviews Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Teaching Vaccine Safety Communication to Medical Students and Health Professionals
Current Drug Safety The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy The Central Role of Leukotriene B4 in Epstein Barr Virus Activated Innate Immunity In Vitro
Current Immunology Reviews (Discontinued) Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Ontogeny of Human Conjugating Enzymes
Drug Metabolism Letters Reducing the Immunogenicity of Protein Therapeutics
Current Drug Targets Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Beta-Adrenoreceptor Modulation of Metabolic, Endocrine and Immunologic Function During Critical Illness
Endocrine, Metabolic & Immune Disorders - Drug Targets Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Children who are Medically Fragile (Guest Editors: Denis Daneman and Jeremy Friedman)]
Current Pediatric Reviews